Search

Your search keyword '"O'Connor, Juan M"' showing total 23 results
Start Over Author "O'Connor, Juan M"
23 results on '"O'Connor, Juan M"'

3. Metastatic pheochromocytoma and paraganglioma: a retrospective multicentre analysis on prognostic and predictive factors to chemotherapy

Author

Pacheco, Samara T, primary, Donadio, Mauro D, additional, Almeida, Felipe, additional, O'Connor, Juan M, additional, De Miguel, Valeria, additional, Dioca, Mariano, additional, Huaman, Jose, additional, Bragagnoli, Arinilda C, additional, Weschenfelder, Rui F, additional, Beltran, Paola M, additional, and Riechelmann, Rachel P, additional

Published
2023
Full Text
View/download PDF

4. Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience

Author

Güttlein, Leandro, primary, Luca, María R, additional, Esteso, Federico, additional, Fresno, Cristóbal, additional, Mariani, Javier, additional, Otero Pizarro, Mercedes, additional, Brest, Esteban, additional, Starapoli, Solange, additional, Kreimberg, Kevin, additional, Teves, Paula, additional, Mendoza Bertelli, Andrea, additional, R Girotti, María, additional, Salanova, Ruben, additional, and O’Connor, Juan M, additional

Published
2022
Full Text
View/download PDF

6. Liquid biopsy for and mutation testing in advanced colorectal cancer patients: the Argentinean experience.

Author

Güttlein, Leandro, Luca, María R, Esteso, Federico, Fresno, Cristóbal, Mariani, Javier, Otero Pizarro, Mercedes, Brest, Esteban, Starapoli, Solange, Kreimberg, Kevin, Teves, Paula, Mendoza Bertelli, Andrea, R Girotti, María, Salanova, Ruben, and O'Connor, Juan M

Subjects
COLON tumors, PROTEINS, GENETIC mutation, RECTUM tumors, RETROSPECTIVE studies, COLORECTAL cancer, HYDROLASES, TRANSFERASES, RESEARCH funding, MEMBRANE proteins
Abstract

Objective: To analyze the frequency of KRAS, NRAS and BRAF hotspot mutations in circulating tumor DNA (ctDNA) from patients with metastatic colorectal cancer (mCRC). Methods: Observational, descriptive and retrospective study in mCRC patients with available ctDNA-based genotype of KRAS, NRAS and BRAF. Results: The frequencies of plasma mutations for KRAS, NRAS and BRAF were 34% (± 7), 4% (± 3) and 4% (± 3), respectively. Median overall survival of plasma-tested RAS/BRAF-mutated patients was 26.6 months (95% CI: 14.4-not estimable [NE]), while RAS/BRAF wild-type patients did not reach the median survival during follow-up. Median progression-free survival for RAS/BRAF wild-type and RAS/BRAF-mutated patients was 12 (95% CI: 7-NE) and 4 months (95% CI: 4-NE), respectively. Conclusion: Our work supports the utility of KRAS, NRAS and BRAF analysis in liquid biopsy from mCRC patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. Health resource utilisation by patients with neuroendocrine tumours with or without carcinoid heart disease: a multinational study

Author

Tanaka, Hugo, primary, Uema, Deise, additional, Rego, Juliana FM, additional, Weschenfelder, Rui F, additional, D'Agustini, Nathalia, additional, Rocha Filho, Duilio R, additional, O'Connor, Juan M, additional, Luca, Romina, additional, Nuñez, Jose Eduardo R, additional, de Barros e Silva, José, additional, and Riechelmann, Rachel P, additional

Published
2020
Full Text
View/download PDF

8. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

Author

Sundin, Anders, Arnold, Rudolf, Baudin, Eric, Cwikla, Jaroslaw B, Eriksson, Barbro, Fanti, Stefano, Fazio, Nicola, Giammarile, Francesco, Hicks, Rodney J, Kjaer, Andreas, Krenning, Eric, Kwekkeboom, Dik, Lombard-Bohas, Catherine, O'Connor, Juan M, O'Toole, Dermot, Rockall, Andrea, Wiedenmann, Bertram, Valle, Juan W, Vullierme, Marie-Pierre, Ferone, D, Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP, Erasmus MC other, and Radiology & Nuclear Medicine

Subjects
Positron emission tomography, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Single photon emission computed tomography, Single-photon emission computed tomography, Neuroendocrine tumors, Scintigraphy, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Cellular and Molecular Neuroscience, Magnetic resonance imaging, Hybrid imaging, NET, 0302 clinical medicine, Endocrinology, Neuroendocrine tumor, Ultrasound, Biopsy, medicine, Computed tomography, Lymph node, medicine.diagnostic_test, Manchester Cancer Research Centre, Endocrine and Autonomic Systems, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Somatostatin receptor imaging, medicine.disease, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Radiology, Nuclear medicine, business, Preclinical imaging
Abstract

Contrast-enhanced computed tomography (CT) of the neck-thorax-abdomen and pelvis, including 3-phase examination of the liver, constitutes the basic imaging for primary neuroendocrine tumor (NET) diagnosis, staging, surveillance, and therapy monitoring. CT characterization of lymph nodes is difficult because of inadequate size criteria (short axis diameter), and bone metastases are often missed. Contrast-enhanced magnetic resonance imaging (MRI) including diffusion-weighted imaging is preferred for the examination of the liver, pancreas, brain and bone. MRI may miss small lung metastases. MRI is less well suited than CT for the examination of extended body areas because of the longer examination procedure. Ultrasonography (US) frequently provides the initial diagnosis of liver metastases and contrast-enhanced US is excellent to characterize liver lesions that remain equivocal on CT/MRI. US is the method of choice to guide the biopsy needle for the histopathological NET diagnosis. US cannot visualize thoracic NET lesions for which CT-guided biopsy therefore is used. Endocopic US is the most sensitive method to diagnose pancreatic NETs, and additionally allows for biopsy. Intraoperative US facilitates lesion detection in the pancreas and liver. Somatostatin receptor imaging should be a part of the tumor staging, preoperative imaging and restaging, for which 68Ga-DOTA-somatostatin analog PET/CT is recommended, which is vastly superior to somatostatin receptor scintigraphy, and facilitates the diagnosis of most types of NET lesions, for example lymph node metastases, bone metastases, liver metastases, peritoneal lesions, and primary small intestinal NETs. 18FDG-PET/CT is better suited for G3 and high G2 NETs, which generally have higher glucose metabolism and less somatostatin receptor expression than low-grade NETs, and additionally provides prognostic information.

Published
2017

9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : Radiological, Nuclear Medicine & Hybrid Imaging.

Author

Sundin, Anders, Arnold, Rudolf, Baudin, Eric, Cwikla, Jaroslaw B, Eriksson, Barbro, Fanti, Stefano, Fazio, Nicola, Giammarile, Francesco, Hicks, Rodney J, Kjaer, Andreas, Krenning, Eric, Kwekkeboom, Dik, Lombard-Bohas, Catherine, O'Connor, Juan M, O'Toole, Dermot, Rockall, Andrea, Wiedenmann, Bertram, Valle, Juan W, Vullierme, Marie-Pierre, Sundin, Anders, Arnold, Rudolf, Baudin, Eric, Cwikla, Jaroslaw B, Eriksson, Barbro, Fanti, Stefano, Fazio, Nicola, Giammarile, Francesco, Hicks, Rodney J, Kjaer, Andreas, Krenning, Eric, Kwekkeboom, Dik, Lombard-Bohas, Catherine, O'Connor, Juan M, O'Toole, Dermot, Rockall, Andrea, Wiedenmann, Bertram, Valle, Juan W, and Vullierme, Marie-Pierre

Abstract

Contrast-enhanced computed tomography (CT) of the neckthorax-abdomen and pelvis, including 3-phase examination of the liver, constitutes the basic imaging for primary neuroendocrine tumor (NET) diagnosis, staging, surveillance, and therapy monitoring. CT characterization of lymph nodes is difficult because of inadequate size criteria (short axis diameter), and bone metastases are often missed. Contrast-enhanced magnetic resonance imaging (MRI) including diffusion-weighted imaging is preferred for the examination of the liver, pancreas, brain and bone. MRI may miss small lung metastases. MRI is less well suited than CT for the examination of extended body areas because of the longer examination procedure. Ultrasonography (US) frequently provides the initial diagnosis of liver metastases and contrast-enhanced US is excellent to characterize liver lesions that remain equivocal on CT/MRI. US is the method of choice to guide the biopsy needle for the histopathological NET diagnosis. US cannot visualize thoracic NET lesions for which CTguided biopsy therefore is used. Endocopic US is the most sensitive method to diagnose pancreatic NETs, and additionally allows for biopsy. Intraoperative US facilitates lesion detection in the pancreas and liver. Somatostatin receptor imaging should be a part of the tumor staging, preoperative imaging and restaging, for which 68 Ga-DOTA-somatostatin analog PET/CT is recommended, which is vastly superior to somatostatin receptor scintigraphy, and facilitates the diagnosis of most types of NET lesions, for example lymph node metastases, bone metastases, liver metastases, peritoneal lesions, and primary small intestinal NETs. (18)FDG-PET/CT is better suited for G3 and high G2 NETs, which generally have higher glucose metabolism and less somatostatin receptor expression than low-grade NETs, and additionally provides prognostic information.

Published
2017
Full Text
View/download PDF

10. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System : Well-Differentiated Pancreatic Non-Functioning Tumors

Author

Falconi, Massimo, Bartsch, Detlef Klaus, Eriksson, Barbro, Klöppel, Günter, Lopes, Josém, O'Connor, Juan M, Salazar, Ramón, Taal, Babs G, Vullierme, Marie Pierre, O'Toole, Dermot, Falconi, Massimo, Bartsch, Detlef Klaus, Eriksson, Barbro, Klöppel, Günter, Lopes, Josém, O'Connor, Juan M, Salazar, Ramón, Taal, Babs G, Vullierme, Marie Pierre, and O'Toole, Dermot

Published
2012
Full Text
View/download PDF

11. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin

Author

Ahlman, Håkan, Nilsson, Ola, McNicol, Anne M., Ruszniewski, Philippe, Niederle, Bruno, Ricke, Jens, Jensen, Robert, Kos-Kudła, Beata, Öberg, Kjell, O'Connor, Juan M., Pavel, Marianne E., Vullierme, Marie-Pierre, Ahlman, Håkan, Nilsson, Ola, McNicol, Anne M., Ruszniewski, Philippe, Niederle, Bruno, Ricke, Jens, Jensen, Robert, Kos-Kudła, Beata, Öberg, Kjell, O'Connor, Juan M., Pavel, Marianne E., and Vullierme, Marie-Pierre

Published
2008
Full Text
View/download PDF

12. Gastrinoma (duodenal and pancreatic)

Author

Jensen, Robert T., Niederle, Bruno, Mitry, Emmanuel, Ramage, John K., Steinmueller, Thomas, Lewington, V., Scarpa, Aldo, Sundin, Anders, Perren, Aurel, Gross, David, O'Connor, Juan M., Pauwels, Stanislas, Kloeppel, Guenter, Jensen, Robert T., Niederle, Bruno, Mitry, Emmanuel, Ramage, John K., Steinmueller, Thomas, Lewington, V., Scarpa, Aldo, Sundin, Anders, Perren, Aurel, Gross, David, O'Connor, Juan M., Pauwels, Stanislas, and Kloeppel, Guenter

Published
2006
Full Text
View/download PDF

13. Gastrinoma (duodenal and pancreatic).

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de médecine nucléaire, Jensen, Robert T, Niederle, Bruno, Mitry, Emmanuel, Ramage, John K, Steinmuller, Thomas, Lewington, V, Scarpa, Aldo, Sundin, Anders, Perren, Aurel, Gross, David, O'Connor, Juan M, Pauwels, Stanislas, Kloppel, Gunter, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de médecine nucléaire, Jensen, Robert T, Niederle, Bruno, Mitry, Emmanuel, Ramage, John K, Steinmuller, Thomas, Lewington, V, Scarpa, Aldo, Sundin, Anders, Perren, Aurel, Gross, David, O'Connor, Juan M, Pauwels, Stanislas, and Kloppel, Gunter

Published
2006

14. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors

Author

Falconi, Massimo, primary, Bartsch, Detlef Klaus, additional, Eriksson, Barbro, additional, Klöppel, Günter, additional, Lopes, José M., additional, O'Connor, Juan M., additional, Salazar, Ramón, additional, Taal, Babs G., additional, Vullierme, Marie Pierre, additional, and O'Toole, Dermot, additional

Published
2012
Full Text
View/download PDF

15. Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin

Author

Ahlman, Hakan, primary, Nilsson, Ola, additional, McNicol, Anne M., additional, Ruszniewski, Philippe, additional, Niederle, Bruno, additional, Ricke, Jens, additional, Jensen, Robert, additional, Kos-Kudła, Beata, additional, Öberg, Kjell, additional, O’Connor, Juan M., additional, Pavel, Marianne E., additional, and Vullierme, Marie-Pierre, additional

Published
2007
Full Text
View/download PDF

18. Gastrinoma (Duodenal and Pancreatic)

Author

Jensen, Robert T., primary, Niederle, Bruno, additional, Mitry, Emmanuel, additional, Ramage, John K., additional, Steinmüller, Thomas, additional, Lewington, V., additional, Scarpa, Aldo, additional, Sundin, Anders, additional, Perren, Aurel, additional, Gross, David, additional, O’Connor, Juan M., additional, Pauwels, Stanislas, additional, and Klöppel, Günter, additional

Published
2006
Full Text
View/download PDF

19. Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study.

Author

Uema, Deise, Alves, Carolina, Mesquita, Marcella, Nuñez, Jose Eduardo, Siepmann, Timo, Angel, Martin, Rego, Juliana F. M., Weschenfelder, Rui, Rocha Filho, Duilio R., Costa, Frederico P., Barros, Milton, O'Connor, Juan M., Illigens, Ben M., and Riechelmann, Rachel P.

Subjects
NEUROENDOCRINE tumors, CARCINOID, LATIN American studies, HEART diseases, BONE metastasis
Abstract

The background to this study was that factors associated with carcinoid heart disease (CHD) and its impacts on overall survival (OS) are scantly investigated in patients (pts) with neuroendocrine tumors (NETs). In terms of materials and methods, a retrospective multicenter cohort study was conducted of factors associated with CHD in advanced NET pts with carcinoid syndrome (CS) and/or elevated urinary 5-hidroxyindole acetic acid (u5HIAA). CHD was defined as at least moderate right valve alterations. The results were the following: Among the 139 subjects included, the majority had a midgut NET (54.2%), 81.3% had CS, and 93% received somatostatin analogues. In a median follow-up of 39 months, 48 (34.5%) pts developed CHD, with a higher frequency in pts treated in public (77.2%) versus private settings (22.9%). In a multivariate logistic regression, unknown primary or colorectal NETs (Odds Ratio (OR) 4.35; p = 0.002), at least 50% liver involvement (OR 3.45; p = 0.005), and being treated in public settings (OR 4.76; p = 0.001) were associated with CHD. In a Cox multivariate regression, bone metastases (Hazard Ratio {HR} 2.8; p = 0.031), CHD (HR 2.63; p = 0.038), and a resection of the primary tumor (HR 0.33; p = 0.026) influenced the risk of death. The conclusions were the following: The incidence of CHD was higher in pts with a high hepatic tumor burden and in those treated in a public system. Delayed diagnosis and limited access to effective therapies negatively affected the lives of NET patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

23. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin.

Author

Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kudła B, Oberg K, O'Connor JM, Pavel ME, and Vullierme MP

Subjects
Digestive System metabolism, Humans, Carcinoma, Neuroendocrine etiology, Carcinoma, Neuroendocrine metabolism, Carcinoma, Neuroendocrine pathology, Digestive System pathology, Gastrointestinal Neoplasms etiology, Gastrointestinal Neoplasms metabolism, Gastrointestinal Neoplasms pathology
Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results